Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients
Open-label Phase I-II Clinical Trial to Evaluate Treatment With Myocet/Taxotere/Herceptin as Primary Chemotherapy Treatment for HER2neu Positive Breast Cancer Patients
Sponsor: Amgen
Listed as NCT00129896, this PHASE1/PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Amgen, it has been updated 9 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Mar 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Cephalon
- Hoffmann-La Roche
- Sanofi
- Spanish Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alcoy, Spain , Alzira, Spain , Badajoz, Spain , Badalona, Spain , Barcelona, Spain , Donostia / San Sebastian, Spain , Jaén, Spain , Lugo, Spain , Manresa, Spain and 5 more locations